RxDoctor Payments DataLook up a doctor →

Joseph Gira, MD

Ophthalmology · Des Peres, MONPI 1861481152

Payments from drug & device makers

$925,979in general payments, 2019–2025

Across 1,521 payments — averaging $608.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$473K
  • Bausch Health US, LLC$129K
  • Kala Pharmaceuticals, Inc.$90K
  • Carl Zeiss Meditec Production LLC$33K
  • Bausch & Lomb Americas Inc.$28K
  • Beaver-visitec International, Inc.$27K
  • plus $146K from 42 others
$405,160in research payments, 2019–2025

Across 40 payments — averaging $10,129 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$194K
  • Bausch & Lomb Americas Inc.$124K
  • Beaver-visitec International, Inc.$84K
  • Glaukos Corporation$3K

What the payments were for

  • Consulting fees$68,16539%
  • Speaking & faculty fees$16,3969%
  • Travel & lodging$29,43517%
  • Food & beverage$51,27129%
  • Education$180%
  • Gifts$190%
  • Entertainment$1,5761%
  • Other$7,4754%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$925,979 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$419,646
Medicare patients
630
Services billed
1,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BesivanceBesifloxacin Hcl27$6,056
Lotemax SmLoteprednol Etabonate19$5,318
Prednisolone Acetate148$4,910
ProlensaBromfenac Sodium13$4,541
Ketorolac Tromethamine152$3,235
Ofloxacin113$1,029
Latanoprost27$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Lotemax Sm, Prolensa$6,552$15,91559 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Missouri.

Other ophthalmology in Des Peres

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →